Halozyme’s Elektrofi Move Redraws the Map for Drug Delivery

MARKET TRENDS

16 Oct 2025

Halozyme’s Elektrofi Move Redraws the Map for Drug Delivery

A push to make high-dose biologics easier and faster to deliver

The $900M Shot at Reinventing Biologic Delivery

TECHNOLOGY

15 Oct 2025

The $900M Shot at Reinventing Biologic Delivery

Halozyme’s Elektrofi deal could turn complex infusions into quick, patient-friendly injections

Biologic Breakthrough or Bet? Axio and Likarda Join Forces

PARTNERSHIPS

14 Oct 2025

Biologic Breakthrough or Bet? Axio and Likarda Join Forces

New partnership weaves delivery into early biologic design, sparking cautious optimism for future impact

Wearables and Biologics Push Care Beyond the Clinic

INSIGHTS

13 Oct 2025

Wearables and Biologics Push Care Beyond the Clinic

US firms pioneer wearable and greener drug-delivery systems as biologics reshape patient care

A $900 Million Shot: Halozyme Targets Smoother Drug Delivery

RESEARCH

10 Oct 2025

A $900 Million Shot: Halozyme Targets Smoother Drug Delivery

Halozyme’s $900M Elektrofi deal aims to speed up and simplify injectable biologic treatments

Faster Shots for Cancer Care: Merck’s Keytruda Qlex Debuts

INNOVATION

8 Oct 2025

Faster Shots for Cancer Care: Merck’s Keytruda Qlex Debuts

Merck’s subcutaneous Keytruda Qlex offers faster cancer dosing, though IV remains the mainstay for most patients.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.